Proactive Investors - Run By Investors For Investors

ValiRX confirms online publication of peer-reviewed article

VAL401 is a new formulation of the antipsychotic drug risperidone
ValiRX confirms online publication of peer-reviewed article
The article can now be read online

Drug developer ValiRx Plc (LON:VAL) has confirmed its peer-reviewed article analysing the used of lead drug, VAL401, has now been published online in the European Journal of Drug Metabolism and Pharmacokinetics.

The academic work focuses on data from a phase II study, completed last year in Tbilisi, Georgia.

READ: New long-term NHS plan bodes well for ValiRx

ValiRx said in December the report was intended to be the first in a series of results-based publications on the treatment.

VAL401 is a new formulation of the antipsychotic drug risperidone, which researchers have transformed into a potential oncology treatment.

The article can be viewed by clicking on this link here.

View full VAL profile View Profile

ValiRx Plc Timeline

Related Articles

scientist in lab
December 18 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use